Hybridon Inc. was formed in 1991 by the Medical Sciences Partners investment group. It's purpose is medical research, in particular cancer research. It is based in Cambridge, Massachussets and has occupied various other locations near Boston. Hybridon is a public company and trades under HYBN.
The company attempts to use the latest DNA technology to combat cancer, by producing antisense drugs. The company has over 70 different patents for all sorts of drugs, and is conducting clinical trials on three. Of these three, GEM 231, is particularly promising. GEM is a registered trademark.